Jos Bloemers

Also affiliated with UCB Pharma (Netherlands), UCB Pharma (Belgium)

MedicinePsychology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study”.

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

Therapeutic Advances in Neurological Disorders(2024)10.1177/17562864241243186

N/A

0.992DataRank · unranked

38 citations

Saskia Bresch, Constantine Farmakidis, Miriam Freimer, Angela Genge, Channa Hewamadduma +23 more

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study

Therapeutic Advances in Neurological Disorders(2025)10.1177/17562864251347283

N/A

0.344DataRank · unranked

6 citations

Urvi Desai, Raghav Govindarajan, Min Kyun Kang, Shaida Khan, Bhupendra Khatri +11 more